Biotech | December 09, 2025
AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
The launch of the study was on the occasion of the International Day of Persons with Disabilities
76 of 180 long COVID-associated genes also linked to ME
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Subscribe To Our Newsletter & Stay Updated
